LumiThera Named Most Promising and Innovative Catalyzer Startup at BIOVISION 2016

SEATTLE, April 27, 2016 /PRNewswire/ — LumiThera ® Inc., a late-stage developmental medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has been awarded the prestigious “MOST PROMISING AND INNOVATIVE CATALYZER AWARD” during Biovision 2016, Lyon, France. Biovision is a high-level investor event connecting industrial partners, financial… Continue reading →

SEATTLE, March 24, 2016 /PRNewswire/ — LumiThera Inc., a developmental stage medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has obtained Health Canada approval of their LIGHTSITE clinical study to treat dry Age-related Macular Degeneration (AMD) subjects. The pilot clinical trial is in part sponsored by… Continue reading →

SEATTLE, Sept. 29, 2015 /PRNewswire/ — LumiThera Inc., a developmental stage medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a two small business innovative research (SBIR) phase I grants from the National Institute of Health (NIH) and the division of the National… Continue reading →

SEATTLE, May 27, 2015 /PRNewswire/ — LumiThera Inc., a developmental stage medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, announced today that they were awarded a Washington State Life Sciences Discovery Fund (LSDF) commercialization grant. LumiThera was 1 of 3 recipients of the LSDF matching grants worth $500,000 to… Continue reading →

Clark E. Tedford,¹ Scott DeLapp,¹ Steven Jacques,² and Juanita Anders³ ¹LumiThera, Inc., Poulsbo, Washington 98370 ²Oregon Health and Science University, Portland, Oregon ³Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 Background and Objective: Photobiomodulation (PBM) also known as low-level light therapy has been used successfully for the… Continue reading →

SEATTLE, May 6, 2015 /PRNewswire/ — LumiThera Inc., a medical device company focused on the development of non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, today announced Retired Congressman Norman Dicks has agreed to join LumiThera’s Advisory Board to assist in the company’s mission to treat vision impairment. Norman DeValois “Norm” Dicks was the… Continue reading →

Passarella S, Karu T. Institute of Laser and Information Technologies of the Russian Academy of Sciences, 142190 Troitsk, Moscow Region, Russian Federation. Abstract In addition to the major functions performed by in the cell, mitochondria play a major role in cell-light interaction. Accordingly it is generally accepted that mitochondria are crucial in cell photobiomodulation; however… Continue reading →

SEATTLE, June 9, 2014 /PRNewswire/ – LumiThera Inc., a medical device company focused on the development of non-invasive light emitting diode (LED) treatments for ocular disorders and disease, today announced Ret. Major General Gale Pollock has joined their Scientific Advisory Board. The first woman to serve as Acting Surgeon General of the United States Army… Continue reading →

United Nations Headquarters (New York) presentation to the Global Health Impact Forum, 6th May 2014 by co founder James Carroll This 15 minute video starts with an overview of Photobiomodulation and low level light therapy as it relates to his company THOR Photomedicine. Later in the presentation James introduces Lumithera and our treatment for Age related… Continue reading →

Begum R, Powner MB, Hudson N, Hogg C, Jeffery G Institute of Ophthalmology, University College London, London, United Kingdom. Abstract Inflammation is an umbrella feature of ageing. It is present in the aged retina and many retinal diseases including age-related macular degeneration (AMD). In ageing and in AMD mitochondrial function declines. In normal ageing this… Continue reading →

LumiThera Named Most Promising and Innovative Catalyzer Startup at BIOVISION 2016

LumiThera Obtains Approval by Health Canada to Start Age-related Macular Degeneration Clinical Study

LumiThera Receives Notice of Awards for two National Eye Institute Grants

LumiThera Receives LSDF Commercialization Grant Award

Quantitative Analysis of Transcranial and Intraparenchymal Light Penetration in Human Cadaver Brain Tissue

Retired Congressman Norman Dicks Joins LumiThera’s Advisory Team

Absorption of Monochromatic and Narrow Band Radiation in the Visible and Near IR by Both Mitochondrial and Non-Mitochondrial Photoacceptors Results in Photobiomodulation

Retired Major General Gale Pollock Joins LumiThera’s Scientific Advisory Board

Video Introduction

Treatment with 670 nm Light Upregulates Cytochrome C Oxidase Expression and Reduces Inflammation in an Age-Related Macular Degeneration Model